Minutes from the Extraordinary General Meeting in Curasight A/S

Report this content

Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the COVID-19 situation, the extraordinary general meeting will be held as a completely electronic meeting without physical attendance.

The agenda for the general meeting was as follows:

  1. Election of Dr. Kirsten Drejer as new member of the board of directors

Dr. Kirsten Drejer was elected as new member of the board of directors. A list of Dr. Kirsten Drejer’s management positions in other companies is enclosed as appendix 1.

  1. Miscellaneous

There were no matters to be presented.


Appendix 1

Dr. Kirsten Drejer’s current board directorships and management positions

2000 -                   KD Invest ApS, CEO

2017 -                   Bioneer A/S (www.bioneer.dk), Chairman of the board

2017 -                   Antag Therapeutics ApS (www.antag.com), Chairman of the board

2017 -                   ResoTher Pharma A/S (www.resotherpharma.com), Chairman of the board

2018 -                   Zealand Pharma A/S (www.zealandpharma.com), Board member


For more information regarding Curasight A/S, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com


Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.


Documents & Links